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Received October 31, 2011; accepted June 26, 2012AbstractBackground: The association between genetic polymorphisms of ADRb2, IL-4, and ADAM3 and asthma remains undetermined. Furthermore,
it is not clear as to whether these three gene polymorphisms combined produce a correlative increase in asthmatic risk.
Methods: A total of 476 asthmatic patients and 115 healthy volunteers were enrolled. Single nucleotide polymorphisms (SNPs) of the C-589T
IL-4 promoter (rs2243250), the ADRb2 gene [at nucleic acid 46 (rs1042713) and 79 (rs1042714)] and the ADAM33 gene [at rs2280091 (T1),
rs3918396 (S1), rs3918391 (D1), and rs615436] were analyzed. Pulmonary function tests, methacholine challenge tests, total IgE, specific IgE
for inhalant allergens and total eosinophil counts were assessed.
Results: The T allele for the IL-4 gene promoter (C-589T locus), the C allele frequency for ADRb2 (Gln27Glu locus), and the A allele for the
ADAM33 gene (rs2280091, T1) were higher in asthma patients than in normal individuals. In asthmatic patients, the A allele of ADAM33
(rs2280091) was associated with higher eosinophil count and increased hyperresponsiveness compared to the C allele. Combination of the three
risk genes SNP had an additive effect on the risk of asthma (OR: 3.46; CI: 1.51e7.93) and increased the diagnostic sensitivity and specificity of
asthma.
Conclusion: Genetic polymorphism in the IL-4 promoter, ADRb2, and ADAM33 is associated with asthma. Furthermore, ADAM33 genetic
polymorphism modifies the phenotype of asthma in atopy and hyperresponsiveness. Asthma is a complex polygenic disease, and combinations of
polymorphisms of various genes have an additive effect on the risk of asthma.
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Asthma is characterized by intermittent airway obstruction
and respiratory symptoms that are related to chronic airway
inflammation and remodeling.1e3
Multiple genes may be involved in the pathogenesis of
asthma,4,5 and different genes may be involved in different
ethnic groups. Previous studies have used genetic linkage
techniques to identify human chromosome 5q31-33 as a region
likely to contain genes related to asthma,6 elevated serumhinese Medical Association. All rights reserved.
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responsiveness (AHR).9 Among the candidate genes in this
region is the gene encoding interleukin-4 (IL-4) and the b2-
adrenergic receptor (ADRb2). Furthermore, a positional
cloning strategy has recently identified a disintegrin and
metalloprotease 33 (ADAM33) in chromosome 20p13 as
a susceptibility factor of asthma.10
A unique function of IL-4 is to promote differentiation of
Th2, and it therefore acts at a proximal and critical site in the
allergic response. IL-4 is critical to the synthesis of IgE by B-
lymphocytes and is also involved in eosinophil recruitment to
the airways.11 Genetic variants of the promoter region of the
IL-4 gene12 have been related to elevated levels of serum IgE.
Because IL-4 stimulation can influence mast cell responsive-
ness to IgE-mediated signaling,13 and genetic variants in the
IL-4 promoter have the capacity to modify IL-4 gene tran-
scription, these sequence variants might be able to modify
asthma. Previous studies have shown an association between
IL-4 promoter polymorphism and asthma.14e17
Beta-2-adrenergic receptor (ADRb2) mediate the actions of
catecholamines which modulate the smooth muscle of the
respiratory tree to keep airway patent. The ADRb2 gene
contains several common genetic variations that affect gene
expression and receptor function in vitro.18,19 The Gly16 allele
of the ADRb2 gene was correlated with more severe
asthma20,21 characterized by corticosteroid use and nocturnal
symptoms,22e24 whereas individuals homozygous for Arg16
had lower lung function.25 The Glu27 allele of ADRb2 gene
was associated with a decrease in airway responses,26e28
whereas Gly16 was associated with asthma suscepti-
bility.23,29,30 The results of ADRb2 genetic polymorphism
association studies in asthma were inconsistent.31e33
A disintegrin and metalloprotease 33 (ADAM33) is abun-
dantly expressed in smooth muscle and subepithelial fibro-
blasts.34,35 Expression within the structural cells of the airway
wall is consistent with the hypothesis that ADAM33 is
involved in airway hyper-responsiveness as an asthma-linked
phenotype.36 Recent studies have shown that the association
of ADAM33 polymorphisms with asthma and related pheno-
types was found in four unique asthma populations (Afri-
caneAmerican, US white, US Hispanic and Dutch white),37
German,38 Japanese39 and Korean.40 However, no associa-
tion was noted in Latino populations (Puerto Rican and
Mexican),41 the North American population of childhood
asthma patients,42 German,43 or Chinese.44
IL-4, ADRb2, and ADAM33 play different roles in the
pathogenesis of asthma; therefore, we propose that these
three genes might be candidate genes of asthma in the
Taiwanese population and that combining these genetic
polymorphisms might increase the risk of asthma. To
address this issue, a prospective case control study
approach was used to attempt to find an association between
a genetic variant of these genes and the presence of either
asthma or one of the specific phenotypes of asthma.
Furthermore, we attempt to ascertain whether, when
combined, these genetic polymorphisms have an additive
effect on the risk of asthma.2. Methods2.1. Study groupAsthmatic patients were enrolled based on clear-cut diag-
nostic criteria and were regularly followed-up in the outpatient
clinic of Taipei Veterans General Hospital in Taiwan from
2000 to 2006. A total of 476 patients with asthma (age:
46  20; 245 male, 231 female; FEV1% predict:
82.6  44.9%; eosinophils: 251  267.3 cells/mm3; IgE:
381.8  1348.1 kU/ml; 284 atopy and 192 non-atopy) were
recruited. A total of 115 healthy individuals (age: 44  17; 62
male, 53 female) without any history of asthma, atopy and
chronic cough or symptoms of shortness of breath were
enrolled as controls. However, among the same studied pop-
ulation, a different number of patients were recruited to
undertake this various genetic study, there are C-589T IL-4
promoter (452 asthma, 106 control), ADRb2 gene (476
asthma, 115 control) and ADAM33 gene (382 asthma, 115
control). The hospital review board for human studies
approved this study protocol, and informed consent was ob-
tained from each participant obtained prior to participation. To
be eligible for inclusion in this study, asthmatic patients were
required to have all of the following characteristics defined by
the guideline of the Global Initiative for Asthma (GINA)1: (1)
at least two symptoms consistent with asthma (cough, wheeze,
and dyspnea); (2) either a positive bronchial hyper-
responsiveness (AHR) or a positive bronchodilator test,
defined as a 15% increase in baseline FEV1 after broncho-
dilator use; and (3) absence of other pulmonary disorders.
In asthmatic groups, pulmonary function tests, bronchodi-
lator or methacholine bronchial provocation tests were per-
formed to confirm airway obstruction and airway
hyperreactivity, respectively. The pulmonary functions were
assessed using an Automated Body Plethysmograph (6200
Autobox DL, SensorMedics Corporation, Yorba Linda, CA,
USA) according to the guidelines of the American Thoracic
Society.452.2. AHR was measured by bronchial challenge with
methacholineA bronchial provocation test using methacholine was con-
ducted on 345 asthmatic patients using the dosimeter method.
A total of 131 asthmatic patients did not receive this test due to
the presence of moderate obstructive ventilatory impairment
on pulmonary function testing, but they all had a positive
bronchodilator test defined by a 15% increase in baseline
FEV1 after inhaled bronchodilator use. The challenge test
procedure was as follows. Various concentrations of meth-
acholine in diluent (phosphate-buffered saline), were delivered
by a metered nebulizer dosimeter. At each point, FEV1 was
measured. The test was continued until either a reduction of
20%in FEV1 was obtained or the last dose was reached. A
PD20 <1600 mg was regarded as positive. No individual
received b2-adrenergic receptor agonist administration for at
least 24 hours prior to methacholine challenge testing.46
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and specific IgETotal eosinophil count, the IgE value and specific IgE were
measured on blood samples obtained from the asthmatic
patients. The IgEs specific for a number of common inhalant
allergens in Taiwan, namely, Dermatophagoides pter-
onyssinus, Dermatophagoides farinae, Dermatophagoides
microceras, cockroach, cat dander and dog dander, were
assessed by immunoenzymatic fluorescence assays (IgE-FEIA
and RAST-FEIA; Pharmacia CAP system, Uppsala, Sweden).
The results were expressed as kU/L, according to the manu-
facturer’s instructions. All the CAP (Capacity) system assays
were performed according to previously reports.142.4. GenotypingDNA was extracted from blood samples using a commer-
cial kit (QIAamp Blood Kit, Qiagen, Chatsworth, CA, USA).2.5. IL-4 geneThe C/T mutation 589 base pairs (bp) upstream of the
translation start site (GenBank access M23442) in the IL-4
promoter was detected by the loss of a Bsm F1 restriction
site.14A 198-bp fragmentwas amplified fromgenomicDNAand
then digested with Bsm F1 restriction enzyme as described.14 In
the amplification, the 50 primer used was 50-TGGGTAAG
GACCTTATGGACC3-0 (nucleotides-683 to-663) and the 30
PCR primer used 50-GGTGGCATCTTGGAAACTGT-30
(nucleotides-486 to-505). The fragments measured 198 bp for
the (-589T allele) and 120 and 78 bp for the (-589C allele) and
were separated on 2% agarose gels.2.6. ADRb2 geneA 219-bp fragment of the B2AR genewas amplified with the
following primers designed by using Oligo Primer Analysis
Software Version 5 (Molecular Biology Insights, Inc): 50-AGC
CAG TGC GCT TAC CTG CCAGAC T-30 (sense) and 50-GCT
CGAACT TGG CAATGG CTG TGA-30 (antisense). PCR was
performed in a GeneAmp 2400 thermal cycler (PerkineElmer)
in a reaction volume of 25 mL by using 200 ng of DNA,
1.5 mmol/L MgCl2, 200 mmol/L deoxyribonucleoside
triphosphates, 10 pmol of each primer and 0.25 U Taq poly-
merase (Boehringer Mannheim) in standard PCR buffer
(10 mmol/L Tris-HCl [pH 8.3] and 50 mmol/L KCl). PCR
involved an initial denaturation at 95 C for 2 minutes, followed
by 35 cycles of denaturation at 95 C for 40 seconds, annealing
at 60 C for 40 seconds, and extension at 72 C for 40 seconds,
followed by a final extension at 72 C for 5 minutes. Five
microliters of PCR product were electrophoresed on a 2%
agarose gel and visualized with ethidium bromide staining and
UV illumination to check the PCR amplification.
Allele-specific PCRwas performed to assess polymorphisms
at nucleic acid 46, which resulted in a change in the encoded
amino acid at position 16. Five microliters of primary PCRproduct were used as the template for allele-specific PCR. The
primer pairs (upstream for Arg16, 50-CTTCTTGCTGGCACC
CTATA-30; upstream for Gly16, 50-CTT CTT GCT GGC ACC
CTATG-30; downstream, 50-GGC AAT GGC TGT GAT GAC
C-30) were used to delineate the polymorphism at nucleic acid
46 (amino acid 16). A 151-bp fragment of PCR product was
obtained by using the following conditions: 30 cycles of 95 C
for 30 seconds, 62 C for 50 seconds, and 72 C for 30 seconds.
Five microliters of the PCR product were then electrophoresed
on 2% agarose gels.47
PCR-restriction fragment length polymorphism was used to
assess polymorphisms at nucleic acid 79, which resulted in
a change in the encoded amino acid at position 27. PCR
reaction was carried out by using 5 mL of primary PCR
product as a template. A 139-bp fragment of PCR product was
obtained by using the following primers: GCC ATG CGC
CGG ACC ACG AC-30 (sense) and 50-CGC TCG AAC TTG
GCA ATG GCT GTG A-30 (antisense). Thirty cycles of PCR
were carried out at 95 C for 30 seconds, 65 C for 30 seconds,
and 72 C for 30 seconds. The PCR products were digested
with Ita1 restriction enzyme (Roche), run on a 2% agarose gel,
and stained with ethidium bromide.472.7. ADAM33 geneADAM33 genes at rs2280091 (T1), rs3918396 (S1),
rs3918391 (D1), and rs615436 were analyzed. For all SNPs,
primers and probes were obtained from Applied Biosystems
TaqMan SNP Genotyping Assays (Nieuwekerk aan de IJssel,
The Netherlands). Reactions were performed in 15 ml volumes
and contained 10 ng DNA, 1 Taqman Universal Mastermix
(FINNZYMES), 200 nM of each probe and 900 nM of each
primer. Cycling conditions on the ABI PRISM 7700 HT
Sequence Detection System (Applied Biosystems) were 10
min at 95 C followed by 40 cycles of 15 seconds at 92 C and
1 minute at 60 C. End-point fluorescence was measured
immediately after cycling. Alleles were assigned using SDS
2.1 software (AppliedBiosystems).
The primary PCR products of different genes were
sequenced with the ABI Prism 3700 sequencer (Applied
Biosystems) to confirm genotypes’ detection in 30 randomly
selected products from each genotype.2.8. Sensitivity and specificity for asthmatic diagnosis by
combination of three gene genotypesRisk genotypes were defined as IL-4 promoter (TT),
ADRb2 (CC), and ADAM33 (AA). Combination genotypes of
three genes containing one, two or three risks were studied
between the normal and asthma groups.
Sensitivity and specificity was calculated as follows:
Sensitivity ¼ number of asthmatic patients with genetic type
of one, two or three risk homozygous SNP which associated
with asthma/total number of asthmatic patients;
Specificity ¼ total number of normal control individuals e
number of same genetic type of risk homozygous SNP as
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normal control individuals2.9. Statistical analysisThe values for FEV1%, methacholine dose, total IgE, and
total eosinophils count were expressed as the mean  SD. The
frequency genotypes were expressed as number and percentage
of the total number. The correlation between gene polymorphism
and asthma or its phenotypes was examined by Fisher’s
exact test, the c2 test and the Pearson c2 test. An ANOVA test
was used to compare the values for FEV1%, methacholine dose,
total IgE, and total eosinophil count across the three genotypes.
Logistic regression was used to evaluate the synergistic
and interactive effects of these three genes on asthma.
3. Results3.1. Correlation between SNPs of the IL-4 promoter
genotype, ADRb2, or ADAM33 genes and asthmaThe T allele of the C-589T IL-4 promoter genotype, the C
allele of ADRb2 at Gln27Glu locus and the A allele of the
gene of ADAM33 at locus on rs2280091 (T1) were signifi-
cantly higher in asthmatic sufferers than in normal group
(Table 1). However, no association between asthma and SNPTable 1
IL-4 promoter, ADRb2 or ADAM33 associated with asthma.
Genotype Control
(non-asthma)
Asthma Odds
ratio
95% CI
IL-4 promoter
(C-589T locus)
106 452 1.6528 1.1419e2.3922
TT 65 (61.3%) 329 (72.7%)
TC 34 (32.1%) 110 (24.4%)
CC 7 (6.6%) 13 (2.9%)
T allele frequency 0.77 0.85
C allele frequency 0.23 0.15
p 0.031
ADRb2
(Gln27Glu locus)
115 476 1.5687 1.0118e2.4322
CC 85 (73.9%) 400 (84.0%)
CG 29 (25.2%) 66 (13.9%)
GG 1 (0.9%) 10 (2.1%)
C allele frequency 0.87 0.91
G allele frequency 0.14 0.09
p 0.009
ADAM33
(rs2280091, T1)
115 382 1.9336 1.2064e3.0991
AA 88 (76.5%) 329 (86.1%)
AG 24 (20.9%) 51 (13.4%)
GG 3 (2.6%) 2 (0.5%)
A allele frequency 0.87 0.93
G allele frequency 0.13 0.07
p 0.017
Values are presented for the three genotypes as a percentage of total number,
n (%), in the group. A ¼ adenine; C ¼ cytosine; CC ¼ allele with cytosi-
neecytosine homozygote; CI ¼ confidence interval; CT ¼ allele with cyto-
sineethymine heterozygote; G ¼ guanine; OR ¼ odds ratio; T ¼ thymine;
TT ¼ allele with thymineethymine homozygote. The p values are presented
for the genotypes of asthma and control groups; OR and CI are presented for
the allele frequency of asthma and control groups.at amino acids 16 or haplotypes of the ADRb2 gene was
found. We also found no polymorphisms in ADAM33 at locus
rs3918396 (S1), rs3918391 (D1) and rs615436 in the Taiwa-
nese people studied.3.2. Correlation between SNP of the IL-4 promoter,
ADRb2 or ADAM33 genes and other phenotypes of
asthma(Tables 2e7) Among asthmatic patients, we found signifi-
cantly higher eosinophil counts or a lower PD20 dose of
methacholine challenge to be associated with the A allele,
compared to the G allele, of ADAM33 at locus on rs2280091,
but there was no significant difference in total IgE and FEV1
(Table 4). There was no significant difference of FEV1, total
eosinophil count, total IgE, and PD20 dose of methacholine
challenge in SNPs of C-589T, IL-4 promoter or ADRb2 at
Gln27Glu locus of asthmatic patients (Tables 2 and 3).
Comparing the allele of polymorphism in these three genes in
asthmatic patients, we found no difference between asthma
with allergy to common inhalation antigens (mite, cockroach,
dog dander, or cat dander) and asthma without allergy to these
antigens (Tables 5e7).
In both control participants and asthmatic patients, allele
frequency of SNPs of the three candidate asthma genes was
not significantly different in relation to either sex or smoking
habit (male vs. female or non-smoker vs. smoker).3.3. Interaction of these three genes(Tables 8 and 9) Only 377 asthmatic patients and 106 control
participants were completely studied in respect to these three
genes. Interaction of these three genes was found to have an
additive effect on the risk of asthma (OR: 3.46; CI: 1.51e7.93).
Compared with any single risk factor gene, the combined risks
of three gene polymorphism with genotypes tended to increase
diagnostic sensitivity and specificity (Table 9).Table 2
Various genotypes of IL-4 promoter polymorphism did not associate with
mean values of different phenotypes.
Genotype N Mean  SD 95% CI for M p
FEV1 (% predict)
TT 293 84.27  52.73 66.61e98.76 0.67
TC 106 75.59  17.81 76.15e83.02
CC 13 82.69  26.94 78.20e90.32
Eosinophils (cells/mm3)
TT 248 255.40  286.33 219.59e291.21 0.81
TC 82 265.27  240.73 212.37e318.16
CC 13 212.62  183.67 101.62e323.61
Methacoline (PC20, mg/mL)
TT 241 0.91  0.89 0.80e1.02 0.09
TC 77 1.12  0.95 0.91e1.34
CC 11 1.33  0.96 0.68e1.98
IgE (KU/mL)
TT 278 330.29  861.96 228.52e432.06 0.31
TC 93 582.44  2357.20 96.98e1067.90
CC 13 368.28  574.03 21.40e715.17
CI ¼ confidence interval of mean; FEV1 ¼ forced expiratory volume at first
and second breath; M ¼ mean; N ¼ number; SD ¼ standard deviation.
Table 3
Various genotypes of ADRb2-(Gln27Glu locus) did not associate with mean
values of different phenotypes.
Genotype N Mean  SD 95%CI for M p
FEV1 (% predict)
CC 365 83.10  48.16 78.14e88.05 0.88
CG 58 80.72  17.82 75.59e84.96
GG 7 78.86  16.71 63.39e94.32
Eosinophils (cells/mm3)
CC 305 251.14  273.29 220.34e281.93 0.95
CG 52 248.04  230.83 183.77e312.30
GG 5 288.00  297.86 81.84e657.84
Methacoline (PC20, mg/mL)
CC 294 0.98  0.92 0.88e1.09 0.61
CG 45 1.01  0.96 0.73e1.30
GG 6 1.35  0.95 0.36e2.35
IgE (KU/mL)
CC 339 375.73  1395.79 226.615e524.85 0.97
CG 57 433.50  1102.50 140.87e725.93
GG 5 207.22  89.44 96.17e318.27
CI ¼ confidence interval of mean; FEV1 ¼ forced expiratory volume at first
and second breath; M ¼ mean; N ¼ number; SD ¼ standard deviation.
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ADRb2 orADAM33genes and other phenotypes of asthmaThe current study confirmed that there is an association
between the IL-4 promoter polymorphism C-589T and asthma.
Furthermore, this study indicated a possible involvement of
a single nucleotide polymorphism in the IL-4 gene in the
development of asthma, which is consistent with previous
studies in the USA,48 Japan,16 and Germany,49 but contrasts
with the findings from the UK,50 Kuwait,51 and China.52 The
Taiwanese and Chinese populations mainly comprise the same
ethnic group, but there are still some minor differences inTable 4
Various genotypes of ADAM33 (rs2280091) associated with different
phenotypes.
Genotype N Mean  SD 95% CI for M p
FEV1 (% predict)
AA 294 82.59  52.51 76.57e88.62 0.95
AG 45 83.39  20.85 77.13e89.66
GG 2 93.50  4.95 49.03e137.97
Eosinophils (cells/mm3)
AA 236 254.61  256.17 212.75e278.46 0.028
AG 36 373.58  423.69 230.23e516.94
GG 2 75.00  35.36 242.66e392.66
Methacoline (PC20, mg/mL)
AA 225 0.92  0.90 0.80e1.04 0.038
AG 36 0.86  7.48 0.60e1.11
GG 2 2.50  0 2.50e2.50
IgE (KU/mL)
AA 269 370.29  969.08 253.96e486.62 0.85
AG 43 295.97  684.80 85.22e506.72
GG 2 151.5  36.06 172.51e475.51
CI ¼ confidence interval of mean; FEV1 ¼ forced expiratory volume at first
and second breath; M ¼ mean; N ¼ number; SD ¼ standard deviation.ethnic composition. Studies focusing on IL-4 promoter gene
polymorphism are still controversial in China.53 The discrep-
ancy between studies may be due to ethnic composition,
sample size, the extent to which participants were “truly
asthmatic” or differences in control groups.
For IL-4 C-589T , the binding of a transcription factor
increases with the presence of the polymorphic T allele.53 In
the light of association studies, it can be hypothesized that this
SNP may lead to over expression of the IL-4 gene and thus
increase the strength of any IL-4-dependent immunological
reaction.
Our results showed a significantly higher C allele frequency
of the ADRb2 genotype at base 79 in asthmatic patients than
in normal individuals. Our findings support a UK study
showing that glutamine 27 polymorphism is associated with
asthma.29 Glu27 homozygous ADRb2 was related to hyper-
bronchial reactivity of asthmatics in the Beijing region.30
However, in different locus SNPs of the ADRb2 gene in the
USA, ADRb2 polymorphism at Gly16 allele and body mass
index were associated with adult-onset asthma in sedentary but
not in active women.54 In Mexico, there was an association
between ADRb2 at Gly 16 allele and asthma.24 Conversely, In
the UK, no association was noted between ADRb2 poly-
morphism and asthma.32 Moreover, a genetic linkage study in
the USA found no linkage at all between asthma and the
ADRb2 gene.55
We found that polymorphism of the ADAM33 gene is
associated with asthma and further modifies the phenotypes of
asthma (severity of hyperresponsiveness and atopy). There-
fore, we suggest that the ADAM33 gene may be an important
gene for asthma development and remodeling processes. To
our knowledge, our study is the first report of an association
between ADAM33 polymorphism and eosinophilia in patients
with asthma. However, the underlying mechanism is unclear
and needs further investigation.
ADAM33 is expressed in airway smooth muscle, fibro-
blasts, and myofibroblasts, and plays a role in cell signaling,
adhesion and proteolysis.56 Interestingly, the existence of
various ADAM33 isoforms in human embryonic bronchi and
their surrounding mesenchyme indicates its contribution to
smooth muscle development and function. Additionally, its
presence in mesenchymal tissues is thought to cause
‘‘unusual’’ airway formation that leads to the origins of asthma
in early life. Thus, the SNP potentially modulating the cata-
lytic domain of ADAM33 could contribute to asthma patho-
genesis. The association of ADAM33 with asthma phenotypes
as a “susceptibility gene” has been replicated in several
cohorts, and genetic variation in this gene has been linked to
accelerating decline in lung function.57 Recently, Lee and
colleagues applied this genetic knowledge to cell biology and
measured ADAM33 levels in bronchoalveolar lavage fluid and
endobronchial biopsies from patients with asthma.58 They
found a correlation between higher ADAM33 levels and
increased chronic airflow obstruction. ADAM33 has become
not just an asthma susceptibility gene, but also a biomarker for
disease severity, playing a complex cause-and-effect role for
airway remodeling in asthma.
Table 5
Comparison between frequency of the genotypes of the IL-4 gene promoter for normal controls and asthmatic patients with various allergy and non-allergy
phenotypes.
Groups Genotypes Allele frequency
TT CT CC T C p1 p2
Normal 65 (61.3%) 34 (30.4%) 7 (6.3%) 0.77 0.23
Asthma
Allergy to mite
n ¼ 231 159 (68.8%) 67 (29.0%) 5 (2.2%) 0.83 0.17 0.09
Non-allergy to mite
n ¼ 171 124 (72.5%) 41 (24%) 6 (3.5%) 0.85 0.15 0.13 0.41
Allergy to cockroach
n ¼ 106 73 (68.9%) 32 (30.2%) 1 (0.9%) 0.84 0.16 0.08
Non-allergy
n ¼ 296 210 (70.9)% 76 (25.7%) 10 (3.4%) 0.84 0.16 0.13 0.31
Allergy to dog dander
n ¼ 87 66 (75.9%) 21 (24.1%) 0 (0%) 0.88 0.12 0.02
Non-allergy
n ¼ 315 217 (68.9%) 87 (27.6%) 11 (3.5%) 0.83 0.17 0.22 0.15
Allergy to cat dander
n ¼ 31 24 (77.4%) 6 (19.4%) 1 (3.2%) 0.87 0.13 0.25
Non-allergy
n ¼ 371 259 (69.8%) 102 (27.5%) 10 (2.7%) 0.84 0.16 0.08 0.62
High total Ig E
n ¼ 136 102 (75%) 32 (23.5%) 2 (1.5%) 0.87 0.13 0.03
Normal total Ig E
n ¼ 215 161 (74.9%) 47 (21.9%) 7 (3.2%) 0.86 0.14 0.04 0.57
High total eosinophil count
n ¼ 47 35 (74.5%) 10 (21.3%) 2 (4.3%) 0.85 0.15 0.29
Normal 450/ml
n ¼ 278 207 (74.5%) 62 (22.3%) 9 (3.2%) 0.86 0.14 0.03 0.93
Values are presented in the three genotypes as percentage of total number, n (%), in the group. Pearson’s c2 test was used to compare the two groups (normal vs.
asthma with allergy; normal vs. asthma without allergy; asthma with allergy vs. asthma without allergy); To compare three genotypes, P1: normal versus asthma
with allergy or normal versus asthma non-allergy; P2: asthma with allergy versus asthma without allergy.
Table 6
Comparison between frequency of the genotypes of the ADRb2 (Gln27Glu locus) gene promoter for normal control and asthmatic patient with various allergy and
non-allergy phenotypes.
Groups Genotypes Allele frequency
CC CG GG C G P1 value P2 value
Normal 85 (73.9 %) 29 (25.2%) 1 (0.9%) 0.87 0.13
Asthma
Allergy to mite
n ¼ 237 198 (83.5%) 36 (15.2%) 3 (1.3%) 0.91 0.09 0.07
Non-allergy to mite
n ¼ 183 158 (86.3%) 22 (12%) 3 (1.6%) 0.92 0.08 0.01 0.62
Allergy to cockroach
n ¼ 108 89 (82.4%) 19 (17.6%) 0 (0%) 0.91 0.09 0.23
Non-allergy
n ¼ 312 267 (85.6%) 39 (12.5%) 6 (2%) 0.92 0.08 0.01 0.16
Allergy to dog dander
n ¼ 88 72 (81.8%) 15 (17%) 1 (1.1%) 0.90 0.10 0.37
Non-allergy
n ¼ 332 284 (85.5%) 43 (13%) 5 (1.5%) 0.92 0.08 0.08 0.60
Allergy to cat dander
n ¼ 31 26 (83.9%) 5 (16.1%) 0 (0%) 0.92 0.08 0.48
Non-allergy
n ¼ 389 330 (84.8%) 53 (13.6%) 6 (1.5%) 0.92 0.08 0.01 0.74
High total Ig E
n ¼ 147 126 (85.7%) 20 (13.6%) 1 (0.7%) 0.93 0.07 0.06
Normal total Ig E
n ¼ 260 218 (83.8%) 37 (14.2%) 5 (1.9%) 0.91 0.09 0.03 0.59
High total eosinophil count
n ¼ 48 42 (87.5%) 5 (10.4%) 1 (2.1%) 0.93 0.07 0.09
Normal 450/ml
n ¼ 316 267 (84.5%) 45 (14.2%) 4 (1.3%) 0.92 0.08 0.03 0.71
Values are presented in the three genotypes as percentage of total number, n (%), in the group. Pearson’s c2 test was used to compare the two groups (normal vs.
asthma with allergy; normal vs. asthma without allergy; asthma with allergy vs. asthma without allergy); To compare three genotypes, P1: normal versus asthma
with allergy or normal versus asthma non-allergy; P2: asthma with allergy versus asthma without allergy.
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Table 7
Comparison between frequency of the genotypes of the ADMA33 gene at rs2280091 (T1) for normal controls and asthmatic patients with various allergy and non-
allergy.
Groups Genotypes Allele frequency
AA AG GG A G p1 p2
Normal n ¼ 115 88 (76.5%) 24 (20.9%) 3 (2.6%) 0.87 0.13
Asthma
Allergy to mite
n ¼ 196 167 (85.2%) 18 (14.3%) 1 (0.5%) 0.92 0.08 0.06
Non-allergy to mite
n ¼ 131 116 (88.5%) 14 (10.7%) 1 (0.8%) 0.94 0.05 0.04 0.61
Allergy to cockroach
n ¼ 89 77 (86.5%) 12 (13.5%) 0 (0%) 0.93 0.07 0.11
Non-allergy
n ¼ 238 206 (86.6)% 30 (12.6%) 2 (0.8%) 0.89 0.11 0.047 0.67
Allergy to dog dander
n ¼ 59 52 (88.1%) 7 (11.9%) 0 (0%) 0.95 0.05 0.14
Non-allergy
n ¼ 268 231 (86.2%) 35 (13.1%) 2 (0.7%) 0.93 0.07 0.04 0.77
Allergy to cat dander
n ¼ 41 37 (90.4%) 4 (9.8%) 0 (0%) 0.95 0.05 0.15
Non-allergy
n ¼ 286 246 (86.0%) 38 (13.3%) 2 (0.3%) 0.93 0.07 0.04 0.70
High total Ig E
n ¼ 113 100 (88.5%) 13 (11.5%) 0 (0%) 0.94 0.06 0.03
Normal total Ig E
n ¼ 202 171 (84.7%) 29 (14.4%) 2 (3.2%) 0.92 0.08 0.16 0.43
High total eosinophil count
n ¼ 38 31 (81.6%) 6 (15.8%) 1 (2.6%) 0.89 0.11 0.79
Normal 450/ml
n ¼ 237 209 (88.2%) 27 (11.4%) 1 (0.4%) 0.94 0.06 0.01 0.24
Values are presented for the three genotypes as percentage of total number, n (%), in the group. Pearson’s c2 test was used to compare the two groups (normal vs.
asthma with allergy; normal vs. asthma without allergy; asthma with allergy vs. asthma without allergy); To compare three genotypes, P1: normal versus asthma
with allergy or normal versus asthma non-allergy; P2: asthma with allergy versus asthma without allergy.
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was associated with asthma. However, it was found at different
SNP loci in people from different countries. ADAM33 asso-
ciated with asthma was found in the USA at I1,L-1, Mþ1,
T1,T2, Tþ1 SNP ,10 and in the UK at Fþ1, Q-1,S1, S2, STþ4,
V-1, V4.10 An association between asthma and ADAM33 SNP
at STþ7 and V4 was found in Dutch, S2 in African Ameri-
cans, STþ7, T1 and T2 in whites and S2, T1 and T2 in
Hispanics39. SNP of ADAM 33 was associated with asthma at
STþ7 in Germans.40 T1 and haplotype were associated with
hyperresponsiveness in Koreans.43 Two SNPs in strong
linkage disequilibrium (T1 and Tþ1) were marginally asso-
ciated with asthma in the Hispanic cohort.45 Minor alleles of
S11, ST14, and T2 SNPs were over-transmitted to asthma-
affected offspring in Japan .39 In contrast, ADAM33 was not
associated with asthma in Puerto Rican or Mexican pop-
ulations .41 There was no significant association between threeTable 8
The interaction of three genes (IL-4, ADRb2, and ADAM 33) in the same popula
Genotypes IL4/ADRb2/ADAM 33 No. OR
11/11/11 29 1 (asth
12/12/12 5 2.44 (a
12/12/22 41 1.67 (a
12/22/22 168 1.57 (a
22/22/22 240 3.46 (a
No.: number; OR: Odd Ratio; CI: confidence interval; 11: no risk allele; 22: riskSNPs of ADAM33 (7575G/A in intron 6, 11188A/T in intron
19, and 12433T/C in exon 20) and asthma susceptibility in the
Chinese population.47 Furthermore, no single SNPs (Fþ1,
Mþ1, S1, S2, STþ4, STþ5, STþ7, T1, T2 and V4) had any
significant association with asthma in the German population
Similarly, no significant association between any of the 10
SNPs (Fþ1, Q-1, S1, STþ4, STþ7, V-2, V-1, V2, V4, V5) and
asthma was found in Australia.364.2. Interaction of IL-4 ADRb2 and ADAM 33Asthma contains phenotypes such as bronchoconstriction,
airway remodeling, hyperactivity, mucus hypersecretion, and
persistent inflammation. These complex traits might be caused
by different and multiple genes. Our results are the first to
show that the interaction of these three genes has an additive
effect on the risk of asthma and they demonstrate thattion and ethnic group with 377 asthmatic patients and106 control subjects.
95% CI p
ma: 14; control: 15)
sthma:4; control: 1) 0.24e24.78 0.449
sthma:25; control: 16) 0.60e4.62 0.326
sthma:103; contol: 65) 0.69e3.58 0.280
sthma:186; control: 54) 1.51e7.93 0.003
alleles.
Table 9
Sensitivity or specificity of combination with various risk genotypes of three
genes, IL-4, ADRb2, and ADAM 33, in the same population and ethnic group
with 377 asthmatic patients and 106 control subjects.
Groups Genotypes Asthma N Normal N Sensitivity Specificity
3 risks TTCCAA 204 36 0.54 0.66
2 risks TTCCAG 27 15
TTCCGG 2 0
TTCGAA 34 9
TTGGAA 7 1
TCCCAA 60 23 0.36 0.51
CCCCAA 7 4
1 risk TTCGAG 6 2
TTCGGG 0 2
TTGGAG 1 0
TTGGGG 0 0
TCCCAG 13 4
TCCCGG 0 0
CCCCAG 0 2
CCCCGG 0 0
TCCGAA 11 5
TCGGAA 1 0
CCCGAA 0 1
CCGGAA 0 0 0.09 0.84
<1 risk TCCGAG 4 1
CCGGGG 0 0
TCCGGG 0 1
A ¼ adenine; C ¼ cytosine; CC ¼ allele with cytosineecytosine homozygote;
CT ¼ allele with cytosineethymine heterozygote; G ¼ guanine; N ¼ number;
T ¼ thymine; TT ¼ allele with thymineethymine homozygote.
642 C.-H. Chiang et al. / Journal of the Chinese Medical Association 75 (2012) 635e643a combination of the three genetic polymorphisms produces an
increase in the sensitivity and specificity for genetic diagnosis
of asthma. This finding supports the view that asthma is
a complex polygenic disease and that more combined genes
are needed to predict the risk of asthma and to improve the
accuracy of genetic diagnosis of asthma. Based on our find-
ings, each candidate gene might modulate a weak association
with asthma. but a combination of more genes that modulate
the different role of pathogenesis, such as IL4 for persistent
inflammation, ADRb2 for bronchodilatation and ADAM33 for
airway remodeling and hyperactivity in our study, respectively,
have an additive effect on the association with asthma. In the
future, it will be necessary to elucidate all genes and their role
in asthma to reliably make a genetic diagnosis and predict the
risk of asthma.
The results of previous studies of SNPs of IL-4, ADRb2, or
ADAM 33 gene replication have been inconclusive, probably
due to inconsistencies in asthma phenotypes, study designs,
ethnically diverse populations and the rigidity of criteria for
asthmatic enrollment by definite diagnosis or as yet unknown
environmental influences.
However, asthmatic patients in the present study were
strictly enrolled based on clear diagnostic criteria and received
regular long-term follow-up by only one physician at the
outpatient clinic of Taipei Veterans General Hospital, Taiwan.
In conclusion, IL-4, ADRb2 and ADAM 33 are associated
with asthma. Furthermore, the ADAM 33 gene is a disease
modifier in terms of the severity of airway hyperresponsiveness
and eosinophilia. The IL-4 promoter gene is associated with
asthmatic patients who have an allergy to dog dander. Thecombined three genetic polymorphisms have an additive effect
on the risk of asthma and genetic diagnosis of asthma. Asthma is
a complex polygenic disease, which will demand a greater
number of combined genes to improve the genetic diagnosis of
asthma and predict the risk of the disorder.
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